The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adults with moderately to severely active Crohn disease (CD).
Single-Molecule Footprinting reveals that RNA polymerase II (Pol II) occupancy is infrequent at mouse promoters. This results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback